Figure 3
Figure 3. Validation of AE9a target genes. (A) RT-qPCR confirmation of 15 AE9a dysregulated genes shown in Figure 2. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used for normalization. (B) Schematics showing the locations of ChIP-chip peaks (short horizontal bars) in 6 potential AE9a direct target genes. The positions of the predicted transcription initiation sites (arrows) and consensus AML1 sites (TGT/cGGT; asterisks) are indicated. The numbers mean the positions relative to the transcription initiation site (+1). For Cdc25b, an AML1 consensus site is not found near the peak; therefore, the center of the peak is indicated with a triangle. E indicates exon. (C) ChIP assays. ChIP was performed using rabbit–anti-HA, rabbit–anti-AML1, and rabbit-IgG control antibodies, followed by PCR amplification of the ChIP-chip peak regions indicated in panel B.

Validation of AE9a target genes. (A) RT-qPCR confirmation of 15 AE9a dysregulated genes shown in Figure 2. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used for normalization. (B) Schematics showing the locations of ChIP-chip peaks (short horizontal bars) in 6 potential AE9a direct target genes. The positions of the predicted transcription initiation sites (arrows) and consensus AML1 sites (TGT/cGGT; asterisks) are indicated. The numbers mean the positions relative to the transcription initiation site (+1). For Cdc25b, an AML1 consensus site is not found near the peak; therefore, the center of the peak is indicated with a triangle. E indicates exon. (C) ChIP assays. ChIP was performed using rabbit–anti-HA, rabbit–anti-AML1, and rabbit-IgG control antibodies, followed by PCR amplification of the ChIP-chip peak regions indicated in panel B.

Close Modal

or Create an Account

Close Modal
Close Modal